Effect of acetazolamide and furosemide in combination for acute heart failure with volume overload under sodium glucose co-transportor 2 inhibitor - Combination therapy with acetazolamide and furosemide for acute heart failure

Iwahana Togo0 个研究点目标入组 60 人开始时间: 2023年11月29日最近更新: 2024年1月22日

试验速览

暂无简介。

•1) A patient aged 18 years or older at the time of enrollment.
•2) A patient hospitalized for acute heart faiure based on Framingham criteria.
•3) NT-proBNP > 1000pg/mL or BNP > 250pg/mL
•4) A patient who has clinical sign of volume overload. (edema, pleural effusion, ascites or juglar vein retension).
•5) A patients who have taken sodium glucose co-transportor 2 inhibitors (dapagliflozin or empagliflozin) for at least 1 month.
•6) A patient who has provided written informed consent to participate in this study (if the patient can not sign by oneself, it is acceptable that a family or a person following a family writes on behalf).

•1) Receipt of acetazolamide maintenance therapy or intolerance for acetazolamide
•2) Type 1 diabetes
•3) Symptomatic hypotension
•4) A Patient expected to receive intravenous inotropes
•5) A history of acute coronary syndrome, stroke or transient ischemic attack within 3 months before screening.
•6) A history of allergy for sodium glucose co-transportor 2 inhibitor or acetazolamide
•7) Restrictive cardiomyopathy, active myocarditis or hypertrophic obstructive cardiomyopathy
•8) Na >145 mEq/L, Na < 130 mEq/L or K < 3.0 mEq/L
•9) Severe hepatic dysfunction (Child-Pugh class C)
•10) Severe chronic kidney disease (Cre > 3.5mg/dL, eGFR < 20mL/min/1.73m2)
•11) Anurea or hypourea (daily urine output < 400mL)
•12) Renal replacement therapy
•13) Pregnant, possibly pregnant, within 28 days postpartum or nursing women
•14) A patient whom the investigator considers to be ineligible as a subject

发起方

Iwahana Togo